Based on myocardial function and prognostic adverse events,the effect of sakubactril valsartan assisted percutaneous coronary intervention in the treatment of patients with coronary atherosclerosis complicated with myocardial infarction was evaluated
Objective To investigate the clinical effect of sakubatrotril valsartan assisted percutaneous coronary intervention(PCI)in the treatment of patients with coronary atherosclerosis complicated with myocardial infarction.Methods A total of 98 patients with coronary atherosclerosis complicated with myocardial infarction admitted to the emergency department from February 2021 to January 2023 were selected as the study objects.All of them received PCI and were divided into 2 groups with 49 cases in each group by random number method.The control group was given ramipril after surgery,and the observation group was given sacubactril and valsartan after surgery.Compare the safety and prognostic adverse events of the two groups,as well as left ventricular ejection fraction(LVEF),soluble growth stimulation-expressed gene-2 protein(sST2),endothelin(ET),left ventricular end-systolic diameter(LVESD),angiotensin(Ang)Ⅱ,left ventricular end-diastolic diameter(LVEDD),pulmonary artery pressure(PAP),nitric oxide(NO),calcitonin gene-related peptide(CGRP),nitric oxide synthase(NOS),aldosterone(ALD),N-terminal B-type pronatriuretic peptide(NT-proBNP)before and after treatment.Results After 1 month and 3 months of treatment,the LVEF in the observation group was higher than that in the control group,and both LVESD and LVEDD were lower than those in the control group(P＜0.05).Compared with the control group,the NT-proBNP,ALD,ET,sST2,and AngⅡ levels in the observation group were lower,while the CGRP,NO,and NOS levels were higher(P＜0.05).The incidence of adverse events in the observation group was 4.08％(2/49),which was lower than that in the control group(18.37％(9/49))(P＜0.05).The incidence of adverse reactions in the two groups was compared,with the observation group being 6.12％(3/49)and the control group being 10.20％(5/49),with no significant difference(P＞0.05).Conclusions Sakubactril valsartan assisted PCI in the treatment of patients with coronary atherosclerosis complicated with myocardial infarction can improve the cardiac function,regulate neuroendocrine factors and vascular endothelial indexes,and help improve the prognosis of patients.
Myocardial infarctionCoronary atherosclerosisSacubatrol valsartanMyocardial function
NETL
NSTL
万方数据
